| Literature DB >> 34587962 |
Xunwei Deng1,2,3,4, Jingyuan Hou1,2,3,4, Qiaoting Deng1,2,3,4, Zhixiong Zhong5,6,7,8,9.
Abstract
BACKGROUND: The relationship between the APOE gene polymorphism and lipid profiles and atrial fibrillation (AF) remains controversial. The current study purposed to investigate how the APOE gene SNPs (rs429358 and rs7412) and lipid profile are associated with the risk for AF among the Hakka population in southern China.Entities:
Keywords: Apolipoprotein E; Hakka; Southern China; atrial fibrillation; gene polymorphism
Mesh:
Substances:
Year: 2021 PMID: 34587962 PMCID: PMC8482687 DOI: 10.1186/s12944-021-01551-4
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1Flow chart of investigating the correlation of APOE gene polymorphism and lipid profile with the risk of AF

Microarray results of APOE genotypes. A: E2/E2, B: E2/E3, C: E2/24, D: E3/E3, E: E3/34, F: E4/E4
Baseline characteristics, medical history and drug therapy of the study participants
| Variables | AF patients ( | Controls ( | ||
|---|---|---|---|---|
| Baseline characteristics, n (%) | ||||
| Age ≥ 65y | 575(81.44) | 396(59.91) | ||
| Male | 414(58.64) | 393(59.46) | 0.783 | |
| SBP ≥ 140mm Hg | 329(46.60) | 307(46.44) | 0.954 | |
| DBP ≥ 90mm Hg | 242(34.28) | 173(26.17) | ||
| 226(32.01) | 180(27.23) | 0.053 | ||
| Alcohol intake | ||||
| Never | 677(95.89) | 630(95.31) | 0.175 | |
| Former | 15(2.12) | 9(1.36) | ||
| Current | 14(1.98) | 22(3.33) | ||
| Smoking status | ||||
| Never | 542(76.77) | 498(75.34) | 0.101 | |
| Former | 89(12.61) | 70(10.59) | ||
| Current | 75(10.62) | 93(14.07) | ||
| Medical history, n (%) | ||||
| Hypertension | 424(60.06) | 379(57.34) | 0.307 | |
| Diabetes | 206(29.18) | 188(28.44) | 0.764 | |
| CAD | 390(55.24) | 223(33.74) | ||
| HF | 294(41.64) | 63(9.53) | ||
| Drug Therapy, n (%) | ||||
| Statin | 16(2.27) | 12(1.82) | 0.556 | |
| ACEIs | 190(26.91) | 111(16.79) | ||
| ARBs | 148(20.96) | 149(22.54) | 0.479 | |
| BBs | 302(42.78) | 179(27.08) | ||
| MRAs | 275(38.95) | 53(8.02) | ||
| Digoxin | 197(27.90) | 24(3.63) | ||
| Diuretics | 324(45.89) | 91(13.77) | ||
Values for age expressed as mean ± SD
SBP: systolic blood pressure
DBP: diastolic blood pressure
CAD: coronary artery disease
HF: heart failure
ACEIs: angiotensin-converting enzyme inhibitors
ARBs: angiotensin receptor blockers
BBs: β-receptor blockers
MRAs: mineralocorticoid antagonists
Echocardiography results and laboratory data of the study participants
| Variables | AF patients ( | Controls ( | |
|---|---|---|---|
| Echocardiography results | |||
| LAD, mm | 40.23 ± 8.40 | 31.34 ± 4.63 | |
| LVDd, mm | 46.82 ± 8.44 | 43.95 ± 5.75 | |
| LVSd, mm | 33.85 ± 9.17 | 29.44 ± 6.03 | |
| LVEF, % | 54.13 ± 12.84 | 62.20 ± 8.37 | |
| Laboratory data | |||
| TC ≥ 5.2mmol/L, n (%) | 178(18.13) | 48(7.26) | |
| TG ≥ 1.7mmol/L, n (%) | 167(23.65) | 96(14.52) | |
| HDL-C < 1mmol/L, n (%) | 191(27.05) | 166(25.11) | 0.414 |
| LDL-C ≥ 3.4mmol/L, n (%) | 109(15.44) | 18(2.72) | |
| Apo-A1 ≥ 1.6 g/L, n (%) | 38(5.38) | 48(7.26) | 0.153 |
| Apo-B ≥ 1.1 g/L, n (%) | 99(14.02) | 26(3.93) | |
| ALT, U/L | 32.42 ± 25.54 | 26.80 ± 20.05 | |
| AST, U/L | 42.49 ± 43.66 | 29.83 ± 27.88 | |
| UN, mmol/L | 8.24 ± 5.06 | 6.46 ± 3.30 | |
| Scr, umol/L | 125.70 ± 85.70 | 102.51 ± 70.39 | |
| UA, umol/L | 412.45 ± 145.89 | 325.74 ± 110.82 | |
| CRP, mg/L | 46.59 ± 57.46 | 41.81 ± 46.65 | 0.302 |
| WBC, 109/L | 9.53 ± 4.55 | 9.04 ± 4.44 | 0.563 |
LAD: left atrium diameter
LVDd: left ventricular end-diastolic diameter
LVSd: left ventricular end-systolic diameter
LVEF: left ventricular ejection fractions
TC: total cholesterol
TG: triglyceride
HDL-C: high-density lipoprotein cholesterol
LDL-C: low-density lipoprotein cholesterol
Apo-A1: apolipoprotein A1
Apo-B: apolipoprotein B
ALT: alanine aminotransferase
AST: aspartate aminotransferase
UN: urea nitrogen
Scr: serum creatinine
UA: uric acid
CRP: C-reactive protein
WBC: white blood cell
The distributions of APOE genotypes and alleles in patients with AF and control groups
| AF patients ( | Controls ( | χ2 | ||
|---|---|---|---|---|
| Genotype | ||||
| E2/E2 | 4(0.57) | 5(0.76) | 5.32 | 0.379 |
| E2/E3 | 96(13.60) | 98(14.83) | ||
| E2/E4 | 13(1.84) | 14(2.12) | ||
| E3/E3 | 380(53.82) | 378(57.19) | ||
| E3/E4 | 199(28.19) | 151(22.84) | ||
| E4/E4 | 14(1.98) | 15(2.27) | ||
| Allele | ||||
| ε2 | 117(8.29) | 122(9.23) | 3.01 | 0.222 |
| ε3 | 1055(74.72) | 1005(76.02) | ||
| ε4 | 240(16.99) | 195(14.75) | ||
| Hardy-Weinberg equilibrium | χ2 | χ2 |
Fig. 3Linkage disequilibrium (LD) values of the SNPs
Lipid levels and the results of two-way ANOVA with AF groups and the three APOE alleles
| AF groups | ANOVA interaction | ||||||
|---|---|---|---|---|---|---|---|
| ε2( | ε3( | ε4( | AF ( | Non-AF ( | |||
| TC (mmol/L) | 3.737(0.075;3.590–3.884) | 4.253(0.039;4.177–4.329) | 4.512(0.055;4.404–4.621) | 4.404(0.047;4.312–4.496) | 3.930(0.048;3.386–4.025) | 6.189 | |
TG (mmol/L) | 1.045(0.050;0.947–1.143) | 1.264(0.026;1.214–1.315) | 1.490(0.037;1.417–1.562) | 1.380(0.031;1.319–1.441) | 1.153(0.032;1.090–1.216) | 4.478 | |
HDL-C (mmol/L) | 1.275(0.027;1.223–1.327) | 1.240(0.014;1.213–1.267) | 1.188(0.020;1.149–1.226) | 1.248(0.017;1.215–1.280) | 1.221(0.017;1.187–1.254) | 0.214 | 0.808 |
LDL-C (mmol/L) | 1.857(0.053;1.753–1.962) | 2.340(0.028;2.286–2.394) | 2.566(0.039;2.488–2.643) | 2.406(0.033;2.340–2.471) | 2.103(0.034;2.035–2.170) | 3.717 | |
Apo-A1 (g/L) | 1.066(0.023;1.020–1.111) | 1.074(0.012;1.050–1.097) | 1.066(0.017;1.033–1.099) | 1.049(0.014;1.021–1.077) | 1.088(0.015;1.059–1.117) | 0.264 | 0.768 |
Apo-B (g/L) | 0.620(0.017;0.587–0.654) | 0.763(0.009;0.745–0.780) | 0.833(0.013;0.808–0.857) | 0.785(0.011;0.764–0.806) | 0.692(0.011;0.670–0.713) | 4.529 | |
Mean (SD; range)
AF: atrial fibrillation
TC: total cholesterol
TG: triglyceride
HDL-C: high-density lipoprotein cholesterol
LDL-C: low-density lipoprotein cholesterol
Apo-A1: apolipoprotein A1
Apo-B: apolipoprotein B
Fig. 4The effect of APOE allele groups (ε2, ε3 and ε4) and AF groups (AF vs. non-AF) on the levels of TG, TC, LDL-C and Apo-B
Logistic regression analysis for risk factors of AF in the study participants
| Parameters | No. subjects | Non-adjusted | Adjusted | ||
|---|---|---|---|---|---|
| Age | |||||
| (< 65y) | 396 | (Ref.) | (Ref.) | ||
| (≥ 65y) | 971 | 2.937(2.298–3.754) | 2.848(1.894–4.283) | ||
| DBP | |||||
| (< 90mm Hg) | 952 | (Ref.) | (Ref.) | ||
| (≥ 90mm Hg) | 415 | 1.471(1.166–1.857) | 1.556(1.080–2.240) | ||
| no | 961 | (Ref.) | (Ref.) | ||
| yes | 406 | 0.053 | 1.258(0.997–1.588) | 0.683 | 1.079(0.748–1.558) |
| TC | |||||
| (< 5.2mmol/L) | 1141 | (Ref.) | (Ref.) | ||
| (≥ 5.2mmol/L) | 226 | 4.305(3.066–6.045) | 3.879(2.003–7.513) | ||
| TG | |||||
| (< 1.7mmol/L) | 1104 | (Ref.) | (Ref.) | ||
| (≥ 1.7mmol/L) | 263 | 1.823(1.382–2.406) | 1.596(1.053–2.419) | ||
| LDL-C | |||||
| (< 3.4mmol/L) | 1240 | (Ref.) | (Ref.) | ||
| (≥ 3.4mmol/L) | 127 | 6.522(3.913–10.872) | 0.596 | 1.308(0.485–3.527) | |
| Apo-B | |||||
| (< 1.1 g/L) | 1242 | (Ref.) | (Ref.) | ||
| (≥ 1.1 g/L) | 125 | 3.983(2.550–6.222) | 0.459 | 1.380(0.589–3.233) |
OR in adjusted model was adjusted for LAD, LVDd, LVSd, LVEF, ALT, AST, UN, Scr, UA, CAD, HF, use of ACEIs, BBs, MRAs, digoxin and diuretics
OR: odds ratio; CI: confidence interval. Other abbreviations see in Tables 1 and 2